Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173790 | 0.83 | APP (0.50) | APPLMNAMAPT | |
| SCHEMBL29120468 | 0.81 | CYP2C9 (0.53) | APPMAPTMAOA | |
| SCHEMBL4517217 | 0.79 | LMNA (0.64) | APPLMNAMAPTPTGS1 | |
| SCHEMBL18260995 | 0.79 | APP (0.47) | APPLMNAMAOA | |
| SCHEMBL4861264 | 0.78 | LMNA (0.63) | LMNAMAOAPTGS1 | |
| SCHEMBL25378071 | 0.75 | GPR88 (0.44) | APP | |
| SCHEMBL9270450 | 0.75 | ACACB (0.40) | LMNAMAPT | |
| SCHEMBL1588646 | 0.74 | APP (0.50) | APP | |
| SCHEMBL7288111 | 0.73 | LMNA (0.56) | LMNAMAPTMAOAPTGS1 | |
| SCHEMBL19908486 | 0.73 | APP (0.47) | APPLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894059-B1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. (BE) | 2005-05-17 | — | — | US | disclosed |
| EP-1165533-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB SA (BE) | 2004-10-13 | — | — | EP | disclosed |
| US-6797713-B2 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. (BE) | 2004-09-28 | — | — | US | disclosed |
| EP-1418173-A1 | N-(3-butyn-1-yl) N-hydroxyurea | UCB, S.A. (BE) | 2004-05-12 | — | — | EP | disclosed |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2004-03-11 | — | — | US | disclosed |
| US-6686502-B1 | N-HYDROXYL-N-(3-BUTYNYL)-UREA CHEMICAL INTERMEDIATE FOR PIPERIDINE OR PIPERAZINE DERIVATIVES | UCB S.A. (BE) | 2004-02-03 | — | — | US | disclosed |
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6451801-B1 | 1,4-SUBSTITUTED PIPERIDINES AND PIPERAZINES | UCB, S.A. (BE) | 2002-09-17 | — | — | US | disclosed |
| EP-1165533-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058295-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | APP 749/4885LMNA 4146/4885MAPT 3862/4885 |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | APP 749/4885LMNA 4146/4885MAPT 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.